Latest News

STAT Plus: AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill

Last May, Gilead Sciences (GILD) chief executive Daniel O’Day testified before Congress that a revised version of a best-selling HIV pill was a “brand new medicine” and that the company was “absolutely not” aware it was safer than an older version during the early stages of development.

Yet a recently filed lawsuit offers details that purportedly contradict his remarks and, in the process, raises questions about the extent to which Gilead may have deliberately delayed bringing a new treatment to market in order to milk sales of an older, lucrative franchise.

Continue to STAT Plus to read the full story…

Source link

Related posts

Proactive Health Company Thriva Secures £6m Series A Funding Round Taking Total Raised To £7.5m


Cancer And Psoriasis: Is There A Link Between The Two?


MIT Develops Color-Changing Ink; Ford Motor Interested


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy